BDTX Black Diamond Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1701541 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-100.0%
TTM net income YoY-305.0%
TTM EPS YoY-305.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-41.1%
ROA-32.3%
ROIC (approx.)-49.8%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets23.8%
Debt / equity0.00x
Current ratio6.92x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.76x
Accruals ratio-7.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $70.00M | $0 |
| R&D expense | $33.56M | $51.31M |
| SG&A expense | $16.57M | $27.47M |
| Operating income | $12.52M | -$78.78M |
| Pretax income | $22.36M | -$69.68M |
| Income tax | $0 | $0 |
| Net income | $22.37M | -$69.68M |
| EBITDA | $12.85M | -$78.44M |
| EPS (basic) | 0.39 | -1.27 |
| EPS (diluted) | 0.39 | -1.27 |
| Weighted avg. shares (diluted) | 57.56M | 55.03M |
| Balance sheet | ||
| Cash & equivalents | $20.99M | $37.26M |
| Short-term investments | $107.66M | $62.14M |
| Current assets | $132.44M | $101.18M |
| PP&E, net | $365,000 | $1.39M |
| Total assets | $143.01M | $122.64M |
| Current liabilities | $15.73M | $20.57M |
| Total liabilities | $30.80M | $39.35M |
| Shareholders' equity | $112.21M | $83.28M |
| Shares outstanding | 57.14M | 56.64M |
| Cash flow statement | ||
| Operating cash flow | $29.61M | -$62.30M |
| Capital expenditure | — | $0 |
| Free cash flow | — | -$62.30M |
| Investing cash flow | -$44.91M | $16.97M |
| Financing cash flow | -$146,000 | $25.55M |
| Depreciation & amortization | $325,000 | $343,000 |
| Stock-based compensation | $6.63M | $10.63M |
Free plan shows the latest 2 periods; Pro shows all 8 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.